FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality

Biotechnology and Bioengineering

Volumn 114, Issue 3, 2017, Pages 632-644

  Louie, Salina ^a   Haley, Benjamin ^a   Marshall, Brett ^a   Heidersbach, Amy ^a   Yim, Mandy ^a   Brozynski, Martina ^a   Tang, Danming ^a   Lam, Cynthia ^a   Petryniak, Bronislawa ^a   Shaw, David ^a   Shim, Jeongsup ^a   Miller, Aaron ^a   Lowe, John B ^a   Snedecor, Brad ^a   Misaghi, Shahram ^a  

^a GENENTECH INC   (United States)

Author keywords

fucose; fucosylation; fully afucosylated antibody; GDP 4 keto 6 d deoxymannose epimerase GDP 4 keto 6 l galactose reductase (FX); glycans

Indexed keywords

CELL CULTURE; CELLS; CLONING; CYTOLOGY; GENE EXPRESSION; MOLECULES; POLYSACCHARIDES; QUALITY CONTROL;

CHINESE HAMSTER OVARY; COMPARATIVE STUDIES; FUCOSE; FUCOSYLATION; GDP-4-KETO-6-D-DEOXYMANNOSE EPIMERASE/GDP-4-KETO-6-L-GALACTOSE REDUCTASE (FX); GLYCANS; NATURAL KILLER CELLS; QUALITY ATTRIBUTES;

ANTIBODIES;

ANTIBODY; GLYCAN; FUCOSE; GDP-4-KETO-6-DEOXY-D-MANNOSE REDUCTASE; OXIDOREDUCTASE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELL CLONE; CELL CULTURE; CHO CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; CRISPR CAS SYSTEM; FEMALE; FUCOSYLATION; GENE INACTIVATION; HOST CELL; NONHUMAN; QUALITY CONTROL; TARGET CELL; ANIMAL; CHEMISTRY; CRICETULUS; GENE EDITING; GENETICS; HAMSTER; METABOLISM; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES; CHO CELLS; CRICETINAE; CRICETULUS; CRISPR-CAS SYSTEMS; FUCOSE; GENE EDITING; GENE KNOCKOUT TECHNIQUES; KETONE OXIDOREDUCTASES; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84994719296     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.26188     Document Type: Article

References (25)

1. Becker DJ, Lowe JB. 2003. Fucose: Biosynthesis and biological function in mammals. Glycobiology 13(7):41R–53R.
2. Carter PJ. 2011. Introduction to current and future protein therapeutics: A protein engineering perspective. Exp Cell Res 317(9):1261–1269.
3. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819–823.
4. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74(4):288–294.
5. Hu Z, Guo D, Yip SS, Zhan D, Misaghi S, Joly JC, Snedecor BR, Shen AY. 2013. Chinese hamster ovary K1 host cell enables stable cell line development for antibody molecules which are difficult to express in DUXB11-derived dihydrofolate reductase deficient host cell. Biotechnol Prog 29(4):980–985.
6. Hu Z, Zhang H, Haley B, Macchi F, Yang F, Misaghi S, Elich J, Yang R, Tang Y, Joly JC, Snedecor BR, Shen A. 2016. Carboxypeptidase D is the only enzyme responsible for antibody C-terminal lysine cleavage in Chinese hamster ovary (CHO) cells. Biotechnol Bioeng 113(10):2100–2106.
7. Imai-Nishiya H, Mori K, Inoue M, Wakitani M, Iida S, Shitara K, Satoh M. 2007. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: A new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol 7:84.
8. Jefferis R, Lund J, Pound JD. 1998. IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 163:59–76.
9. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. 2013. RNA-programmed genome editing in human cells. Elife 2:00471.
10. Kanda Y, Imai-Nishiya H, Kuni-Kamochi R, Mori K, Inoue M, Kitajima-Miyama K, Okazaki A, Iida S, Shitara K, Satoh M. 2007. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics. J Biotechnol 130(3):300–310.
11. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided human genome engineering via Cas9. Science 339(6121):823–826.
12. Malphettes L, Freyvert Y, Chang J, Liu PQ, Chan E, Miller JC, Zhou Z, Nguyen T, Tsai C, Snowden AW, Collingwood TN, Gregory PD, Cost GJ. 2010. Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng 106(5):774–783.
13. Misaghi S, Chang J, Snedecor B. 2014. It's time to regulate: Coping with product-induced nongenetic clonal instability in CHO cell lines via regulated protein expression. Biotechnol Prog 30(6):1432–1440.
14. Ohyama C, Smith PL, Angata K, Fukuda MN, Lowe JB, Fukuda M. 1998. Molecular cloning and expression of GDP-D-mannose-4,6-dehydratase, a key enzyme for fucose metabolism defective in Lec13 cells. J Biol Chem 273(23):14582–14587.
15. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, Valerius T. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112(6):2390–2399.
16. Raju TS, Briggs JB, Borge SM, Jones AJ. 2000. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10(5):477–486.
17. Ravetch JV, Bolland S. 2001. IgG fc receptors. Annu Rev Immunol 19:275–290.
18. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. 2001. Glycosylation and the immune system. Science 291(5512):2370–2376.
19. Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. 2013. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 5(6):872–881.
20. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277(30):26733–26740.
21. Smith PL, Myers JT, Rogers CE, Zhou L, Petryniak B, Becker DJ, Homeister JW, Lowe JB. 2002. Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus. J Cell Biol 158(4):801–815.
22. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176–180.
23. von Horsten HH, Ogorek C, Blanchard V, Demmler C, Giese C, Winkler K, Kaup M, Berger M, Jordan I, Sandig V. 2010. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. Glycobiology 20(12):1607–1618.
24. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):1393–1398.
25. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87(5):614–622.